CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer's disease

Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively...

Descripción completa

Detalles Bibliográficos
Autores: Warmenhoven, Noëlle, Sánchez Benavides, Gonzalo, González Escalante, Armand, Milà Alomà, Marta, Shekari, Mahnaz, López Martos, David, Ortiz Romero, Paula, 1994-, Kollmorgen, Gwendlyn, Quijano Rubio, Clara, Minguillón, Carolina, Gispert, Juan Domingo, Vilor Tejedor, Natàlia, 1988-, Arenaza Urquijo, Eider M., Palpatzis, Eleni, Ashton, Nicholas J., Zetterberg, Henrik, Blennow, Kaj, Suárez-Calvet, Marc, Grau, Oriol (Grau Rivera), ALFA Study
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2024
País:España
Institución:Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repositorio:Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:oai:recercat.cat:10230/61197
Acceso en línea:http://hdl.handle.net/10230/61197
http://dx.doi.org/10.1002/alz.13862
Access Level:acceso abierto
Palabra clave:Alzheimer&apos
s disease
Chitinase 3‐like protein 1
Cognition
Cognitively unimpaired
Glial biomarkers
Glial fibrillary acidic protein
Preclinical
Soluble triggering receptor expressed on myeloid cell 2
Descripción
Sumario:Introduction: We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are associated with cognitive change in cognitively unimpaired (CU) individuals at risk of Alzheimer's disease (AD). Methods: A total of 353 CU (mean age 60.9 years) participants were included (mean follow-up time 3.28 years). Linear regression models with cognition as outcome were used. We also tested whether amyloid beta (Aβ) status modified these associations. Results: Higher baseline CSF sTREM2 was associated with a positive global cognition (Preclinical Alzheimer's Cognitive Composite) rate of change, and better memory and executive outcomes, independently of AD pathology. Higher baseline plasma GFAP was associated with a decline on attention rate of change. Stratified analyses by Aβ status showed that CSF sTREM2 and YKL-40 were positively associated with executive functioning in amyloid negative (Aβ-) individuals. Discussion: Our results suggest that a TREM2-mediated microglial response may be associated with better longitudinal cognitive performance. Highlights: Higher cerebrospinal fluid (CSF) soluble triggering receptor expressed on myeloid cell 2 (sTREM2) relates to better longitudinal cognitive performance. The association between CSF sTREM2 and cognition is independent of Alzheimer's disease (AD) pathology. Targeting microglial reactivity may be a therapeutic strategy for AD prevention.